Avenue Therapeutics (NASDAQ:ATXI)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Tuesday, AnalystRatings.com reports. They presently have a $11.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 135.55% from the company’s previous close.
Separately, ValuEngine lowered shares of Avenue Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, February 25th.
NASDAQ:ATXI opened at $4.67 on Tuesday. Avenue Therapeutics has a one year low of $2.08 and a one year high of $6.82. The stock has a market capitalization of $76.64 million, a PE ratio of -2.22 and a beta of -0.80.
Avenue Therapeutics (NASDAQ:ATXI) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.39). On average, sell-side analysts expect that Avenue Therapeutics will post -1.64 earnings per share for the current year.
In other Avenue Therapeutics news, Director Neil Herskowitz purchased 5,000 shares of Avenue Therapeutics stock in a transaction dated Monday, February 25th. The stock was acquired at an average price of $5.46 per share, for a total transaction of $27,300.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. In the last 90 days, insiders bought 6,600 shares of company stock valued at $34,886. Company insiders own 5.00% of the company’s stock.
Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC bought a new stake in shares of Avenue Therapeutics in the 1st quarter valued at about $51,000. Northern Trust Corp bought a new position in shares of Avenue Therapeutics during the 4th quarter worth approximately $79,000. Spark Investment Management LLC bought a new position in shares of Avenue Therapeutics during the 1st quarter worth approximately $144,000. National Asset Management Inc. raised its stake in shares of Avenue Therapeutics by 4.7% during the 4th quarter. National Asset Management Inc. now owns 66,250 shares of the company’s stock worth $358,000 after acquiring an additional 3,000 shares in the last quarter. Finally, Opaleye Management Inc. bought a new position in shares of Avenue Therapeutics during the 4th quarter worth approximately $2,678,000. Institutional investors and hedge funds own 4.34% of the company’s stock.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.
Featured Article: What is the Coverage Ratio?
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.